N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: The OMEGA-PAD trial

S. Marlene Grenon, Christopher D. Owens, Hugh Alley, Karen Chong, Priscilla K. Yen, William Harris, Millie Hughes-Fulford, Michael S. Conte

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort. ClinicalTrials.gov Identifier: NCT01310270

Original languageEnglish (US)
Pages (from-to)263-274
Number of pages12
JournalVascular Medicine (United Kingdom)
Volume18
Issue number5
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Peripheral Arterial Disease
Omega-3 Fatty Acids
Dietary Supplements
Inflammation
Blood Vessels
Risk Management
Secondary Prevention
Coronary Artery Disease
Randomized Controlled Trials
Placebos
Guidelines
Morbidity
Mortality
Population

Keywords

  • fatty acids
  • peripheral artery disease
  • randomized controlled trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Grenon, S. M., Owens, C. D., Alley, H., Chong, K., Yen, P. K., Harris, W., ... Conte, M. S. (2013). N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: The OMEGA-PAD trial. Vascular Medicine (United Kingdom), 18(5), 263-274. https://doi.org/10.1177/1358863X13503695

N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease : The OMEGA-PAD trial. / Grenon, S. Marlene; Owens, Christopher D.; Alley, Hugh; Chong, Karen; Yen, Priscilla K.; Harris, William; Hughes-Fulford, Millie; Conte, Michael S.

In: Vascular Medicine (United Kingdom), Vol. 18, No. 5, 10.2013, p. 263-274.

Research output: Contribution to journalArticle

Grenon, SM, Owens, CD, Alley, H, Chong, K, Yen, PK, Harris, W, Hughes-Fulford, M & Conte, MS 2013, 'N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: The OMEGA-PAD trial', Vascular Medicine (United Kingdom), vol. 18, no. 5, pp. 263-274. https://doi.org/10.1177/1358863X13503695
Grenon, S. Marlene ; Owens, Christopher D. ; Alley, Hugh ; Chong, Karen ; Yen, Priscilla K. ; Harris, William ; Hughes-Fulford, Millie ; Conte, Michael S. / N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease : The OMEGA-PAD trial. In: Vascular Medicine (United Kingdom). 2013 ; Vol. 18, No. 5. pp. 263-274.
@article{c5e2b1e882204a2d8e32d3356bd92383,
title = "N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: The OMEGA-PAD trial",
abstract = "Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort. ClinicalTrials.gov Identifier: NCT01310270",
keywords = "fatty acids, peripheral artery disease, randomized controlled trials",
author = "Grenon, {S. Marlene} and Owens, {Christopher D.} and Hugh Alley and Karen Chong and Yen, {Priscilla K.} and William Harris and Millie Hughes-Fulford and Conte, {Michael S.}",
year = "2013",
month = "10",
doi = "10.1177/1358863X13503695",
language = "English (US)",
volume = "18",
pages = "263--274",
journal = "Vascular Medicine (United Kingdom)",
issn = "1358-863X",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease

T2 - The OMEGA-PAD trial

AU - Grenon, S. Marlene

AU - Owens, Christopher D.

AU - Alley, Hugh

AU - Chong, Karen

AU - Yen, Priscilla K.

AU - Harris, William

AU - Hughes-Fulford, Millie

AU - Conte, Michael S.

PY - 2013/10

Y1 - 2013/10

N2 - Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort. ClinicalTrials.gov Identifier: NCT01310270

AB - Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort. ClinicalTrials.gov Identifier: NCT01310270

KW - fatty acids

KW - peripheral artery disease

KW - randomized controlled trials

UR - http://www.scopus.com/inward/record.url?scp=84887007301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887007301&partnerID=8YFLogxK

U2 - 10.1177/1358863X13503695

DO - 10.1177/1358863X13503695

M3 - Article

C2 - 24052491

AN - SCOPUS:84887007301

VL - 18

SP - 263

EP - 274

JO - Vascular Medicine (United Kingdom)

JF - Vascular Medicine (United Kingdom)

SN - 1358-863X

IS - 5

ER -